CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

“CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries to find out that specific antibodies are capable of targeting one unique molecular site of the cancer cells.

“CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023” report highlights:

Market Opportunity Assessment: More than US$ 60 Billion by 2023
Clinical and Patent Insight on 17 Commercialize CD Antigen Drugs
Clinical and Licensing Insight on 184 CD Antigens in Clinical Pipeline
Dosage and Price Analysis on Key Drugs
Mechanism of CD Antigen Cancer Therapeutics
Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

CD antigens have been used as targets in a wide variety of cancer therapeutics including monoclonal antibodies, antibody-drug-conjugates, tri-functional and bi-specific T-cell engager antibodies, radio immunoconjugates and CAR T-cell therapies. The current scenario clearly indicates that CD Antigens have acquired a major share in the modern cancer therapy market. Approval and commercialization of such a wide variety of cancer therapeutics have shown that continuous efforts have been made to produce unique and improved anti-cancer products.

Global CD antigen based cancer therapy market has evolved since the approval of first CD antigen targeting monoclonal antibody. Current market is fledged with a variety of CD antigen targeting cancer therapies. The market has successfully produced unique CD antigen based cancer therapies. Clinical trials of these therapies have provided evidences that they are better than the existing conventional cancer therapies and provide better quality adjusted life years and prolonged survival to cancer patients.

Although current global CD antigen based cancer therapeutic market is dominated for treating hematological malignancies but strong clinical pipeline having over 100 CD antigen directing cancer drugs consists of various drugs which will be used for treating solid tumors like breast cancer, lung cancer, colorectal cancer, prostate cancer etc. As the number of patients suffering from solid tumors is much higher than the patients suffering from hematological malignancies; an exponential growth can be experienced by Global CD Antigen Cancer Therapy Market after the approval of anti-CD antigenic cancer drugs for treating solid tumors.

Approval of CD antigen directed CAR-T cell therapy has further encouraged public and private sectors to increase investments in research studies related to genomics and technological advancements for feasible gene sequencing and selection of target gene expressing CD antigens. Earlier, cancer therapeutics was limited to using CD20 as a target for developing anti-cancer drugs. But with continuous efforts in research more CD antigens were found to play significant roles in cancer progression which were then used as cancer therapeutic targets including CD19, CD22, CD38, CD33 and CD3.

The future CD antigen based cancer therapy market is going to be highly competitive as the pharmaceutical companies have to ensure that they are producing unique and more advanced products. Furthermore, CD antigens based cancer therapies has the potential to become popular amongst the patients and physicians as they provide better survival and have justified their high prices in case of some therapies by providing better clinical results than other conventional cancer therapies.

1. Introduction to CD Antigen Based Cancer Therapeutics

1.1 Prologue to CD Antigens

1.2 Background: Discovering CD Antigens in Cancer Therapy

1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics

2. Significance of CD Antigens: Normal Cells versus Cancer Cells

2.1 CD Antigens in Normal Cells

2.2 CD Antigens in Cancer

3. Working Mechanism of CD Antigen Based Cancer Therapeutics

4. Commercial Cancer Therapeutics Based on CD Antigens

4.1 Monoclonal Antibodies

4.2 Antibody Drug Conjugates

4.3 Bispecific Antibodies

5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics

5.1 CAR-T Cell Therapy

5.2 Aptamers

5.3 Immunoconjugates

5.3.1 Radio Immunoconjugate

5.3.2 Toxin Immunoconjugate

5.4 Novel CD Antigen Based Antibodies

5.4.1 Bispecific T-Cell Engager Antibody (BiTEs)

5.4.2 DART and TandAb

6. Major CD Antigens as Targets for Cancer Therapy

6.1 CD20

6.2 CD19

6.3 CD137

6.4 CD38

6.5 CD70

6.6 CD22

6.7 CD30

6.8 CD33

6.9 CD37

7. Major CD Antigens as Cancer Diagnostic Agents

7.1 CD20

7.2 CD5

7.3 CD56

7.4 CD66e

7.5 CD15

7.6 CD30

7.7 CD3

8. Major CD Antigens in Cancer Research

8.1 CD34

8.2 CD10

8.3 CD26

8.4 CD117

8.5 CD44

8.6 CD57

9. Global CD Antigen Based Therapeutics Market Overview

9.1 Market Progression

9.2 Current Market Scenario

9.3 Global CD Antigen Based Cancer Therapeutics Market Trends

9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview

10. Price and Dosage Analysis of Major CD Antigen Based Cancer Therapies

10.1 Rituximab (CD20)

10.2 Ofatumumab (CD20)

10.3 Obinutuzumab (CD20)

10.4 Daratumumab (CD38)

10.5 Brentuximab Vedotin (CD30)

10.6 Gemtuzumab Ozogamicin (CD33)

10.7 Inotuzumab Ozogamicin (CD22)

10.8 Ibritumomab Tiuxetan (CD20)

10.9 Blinatumomab (CD19, CD3)

10.10 Tisagenlecleucel (CD19)

11. Marketed Cancer CD Antigen Inhibitors Clinical and Patent Insight

11.1 Rituximab (MabThera and Rituxan)

11.2 Obinutuzumab (Gazyva and Gazyvaro)

11.3 Ibritumomab Tiuxetan (Zevalin and Zevamab)

11.4 Rituximab Biosimilar (AcellBia and USMAL)

11.5 Rituximab Biosimilar (Reditux and Tidecron)

11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima and Tuxella)

11.7 Rituximab Biosimilar (Novex)

11.8 Rituximab Biosimilar (RituxiRel, Toritz and Toritz RA)

11.9 Rituximab Biosimilar (Maball)

11.10 Rituximab Biosimilar (Kikuzubam)

11.11 Rituximab Biosimilar (Mabtas)

11.12 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat and Remniq)

11.13 Avelumab (BAVENCIO)

11.14 Pembrolizumab (Keytruda)

11.15 Atezolizumab (TECENTRIQ)

11.16 Durvalumab (Imfinzi)

11.17 Rituximab Biosimilar (Zytux)

12. Global CD Antigen Cancer Therapy Market Dynamics

12.1 Market Growth Drivers

12.1.1 Large Patient Base

12.1.2 Unmet Medical Need

12.1.3 Better Safety Profile

12.1.4 Accelerated Research and Development: Newly Identified CD Antigens in Cancer

12.1.5 Acquiring Major Share of the Modern Cancer Therapy Market

12.1.6 Strong Clinical Pipeline

12.2 CD Antigen Market Challenges

12.2.1 High Prices of CD Antigen Based Cancer Therapeutics

12.2.2 Difficulties in Differentiating CD Target on Cancer Cells

12.2.3 High Production Cost Due to Complex Structure

13. Global CD Antigens Cancer Therapy Market Future Forecast

14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

14.1 Research

14.2 Preclinical

14.3 Phase-I

15. Cancer CD 3 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

15.1 Preclinical

15.2 Phase-I

15.3 Phase-II

16. Cancer CD 4 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

16.1 Phase-I

17. Cancer CD 7 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

17.1 Preclinical

18. Cancer CD 19 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

18.1 Phase-I

18.2 Phase-I/II

18.3 Phase-II

18.4 Phase-III

19. Cancer CD 20 Antigen Inhibiors Clinical Pipeline by Company, Indication and Phase

19.1 Unknown

19.2 Research

19.3 Preclinical

19.4 Clinical

19.5 Phase-I

19.6 Phase-I/II

19.7 Phase-II

19.8 Phase-III

19.9 Registered

20. Cancer CD 22 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

20.1 Preclinical

20.2 Phase-III

20.3 Registered

21. Cancer CD 26 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

21.1 Preclinical

21.2 Phase-I/II

22. Cancer CD 27 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

22.1 Research

22.2 Preclinical

22.3 Phase-II

23. Cancer CD 30 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

23.1 Phase-I

24. Cancer CD 33 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

24.1 Phase-I

24.2 Phase-I/II

25. Cancer CD 38 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

25.1 Research

25.2 Preclinical

25.3 Phase-I/II

25.4 Phase-III

26. Cancer CD 44 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

26.1 Preclinical

26.2 Phase-I

27. Cancer CD 45 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

27.1 Phase-III

28. Cancer CD 46 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

28.1 Research

29. Cancer CD 47 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

29.1 Research

29.2 Preclinical

29.3 Phase-I

29.4 Phase-I/II

30. Cancer CD 52 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

30.1 Research

30.2 Preclinical

31. Cancer CD 55 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

31.1 Preclinical

31.2 Phase-II

32. Cancer CD 56 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

32.1 Phase-II

33. Cancer CD 66 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

33.1 Phase-I

34. Cancer CD 70 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

34.1 Phase-II

35. Cancer CD 71 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

35.1 Preclinical

36. Cancer CD 98 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

36.1 Phase-I

37. Cancer CD 200 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

37.1 Preclinical

37.2 Clinical

37.3 Phase-II

38. Cancer CD 223 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

38.1 Preclinical

38.2 Phase-I

38.3 Phase-I/II

38.4 Phase-II

39. Cancer CD 248 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

39.1 Preclinical

39.2 Phase-II

40. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

40.1 Research

40.2 Preclinical

40.3 Clinical

40.4 Phase-I

40.5 Phase-I/II

41. Cancer CD 319 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

41.1 Phase-I

42. Cancer Multiple Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

42.1 Preclinical

42.2 Phase-I

42.3 Phase-I/II

43. Competitive Landscape

43.1 AryoGen Biopharma

43.2 Biocad

43.3 Biogen Idec

43.4 Celltrion

43.5 Genentech

43.6 Genmab

43.7 GLYCART Biotechnology

43.8 Hetero Drugs

43.9 mAbxience

43.10 MedImmune

43.11 Merck

43.12 Sandoz

43.13 UCB

Figure 1-1: Evolution of CD Antigen Based Therapeutic Antibodies in Cancer Therapy

Figure 2 1: CD Antigens as Markers on Normal Leukocytes

Figure 2 2: Significance of CD Antigen in Cancer Cell and its Inhibition by Therapeutic Antibody

Figure 4-1: Types of CD Antigen Based Cancer Therapeutics

Figure 4-2: Structure of Monoclonal Antibody

Figure 4-3: Types of Therapeutic Monoclonal Antibodies

Figure 4-4: Architecture of Antibody Drug Conjugates

Figure 4-5: Bispecific Antibody Structure

Figure 5-1: Advanced CD Antigen Targeting Cancer Therapies

Figure 5-2: Structure of Radio Immunoconjugate

Figure 5-3: Structure of Bispecific T-Cell Engager Antibody

Figure 5-4: Structure of Dual Affinity Re-Targeting Antibody

Figure 6-1: Mechanism of Action of Anti-CD20 Monoclonal Antibody Rituximab

Figure 6-2: Mechanism of Action of Anti-CD30 Antibody Drug Conjugate Brentuximab Vedotin

Figure 9-1: Global - Cancer Therapeutic Monoclonal Antibody Market Share (%), 2017

Figure 9-2: Global - CD20 Cancer Therapeutic Segmentation by Region (%), 2017

Figure 9-3: Global - Rituximab Sales (US$ Billion), 2013-2016

Figure 9-4: Global - Ofatumumab Sales (US$ Million), 2013-2016

Figure 9-5: Global - Obinutuzumab Sales (US$ Million), 2015 and 2016

Figure 9-6: Global - Ibritumomab Tiuxetan Sales (US$ Million), 2013-2016

Figure 9-7: Global - Daratumumab Sales (US$ Million), 2015-2017*

Figure 9-8: Global - Daratumumab Half Yearly Sales (US$ Million), 2016 and 2017

Figure 9-9: Global - Brentuximab Vedotin Sales (US$ Million), 2014-2017

Figure 9-10: Global - Blinatumomab Sales (US$ Million), 2015-2017*

Figure 9-11: Global - Blinatumomab Sales (US$ Million), 2015-2017

Figure 9-12: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-13: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-14: Global - Cancer CD 3 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-15: Global - Cancer CD 3 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-16: Global - Cancer CD 19 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-17: Global - Cancer CD 19 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-18: Global - Cancer CD 20 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-19: Global - Cancer CD 20 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-20: Global - Cancer CD 22 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-21: Global - Cancer CD 22 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-22: Global - Cancer CD 26 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-23: Global - Cancer CD 26 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-24: Global - Cancer CD 27 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-25: Global - Cancer CD 27 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-26: Global - Cancer CD 33 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-27: Global - Cancer CD 33 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-28: Global - Cancer CD 38 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-29: Global - Cancer CD 38 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-30: Global - Cancer CD 44 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-31: Global - Cancer CD 44 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-32: Global - Cancer CD 47 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-33: Global - Cancer CD 47 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-34: Global - Cancer CD 52 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-35: Global - Cancer CD 52 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-36: Global - Cancer CD 55 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-37: Global - Cancer CD 55 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-38: Global - Cancer CD 200 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-39: Global - Cancer CD 200 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-40: Global - Cancer CD 223 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-41: Global - Cancer CD 223 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-42: Global - Cancer CD 248 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-43: Global - Cancer CD 248 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-44: Global - Cancer CD 274 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-45: Global - Cancer CD 274 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-46: Global - Cancer CD Miltiple Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-47: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (Number), 2017

Figure 9-48: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-49: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 10-1: US - Rituximab Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2017

Figure 10-2: US - Rituximab Vial Price by Quantity (US$), 2017

Figure 10-3: Rituximab Treatment Cost Analysis by Route of Administration (US$), 2017

Figure 10-4: US - Ofatumumab Intravenous Solution Price by Concentration (20mg/mL) (US$/Unit), 2017

Figure 10-5: US - Ofatumumab Vial Price by Quantity (US$), 2017

Figure 10-6: Ofatumumab - Treatment Dosage Analysis (mg)

Figure 10-7: Ofatumumab - Price Analysis by Dosage (US$)

Figure 10-8: Obinutuzumab First Cycle Dosage Analysis (mg)

Figure 10-9: Obinutuzumab Treatment Dosage Analysis (mg)

Figure 10-10: US - Obinituzumab Solution Price (US$), 2017

Figure 10-11: Obinutuzumab - Therapy First Cycle Average Cost (US$), 2017

Figure 10-12: Obinutuzumab Average Treatment Cost (US$), 2017

Figure 10-13: Daratumumab Monotherapy Dosage Analysis (mg)

Figure 10-14: Daratumumab Combination Therapy Dosage Analysis (mg)

Figure 10-15: US - Daratumumab Intravenous Solution Cost by Concentration (20mg/mL) (US$/Unit), 2017

Figure 10-16: Daratumumab Vial Price Analysis by Quantity (US$), 2017

Figure 10-17: Daratumumab Monotherapy Average Cost Analysis (US$), 2017

Figure 10-18: Daratumumab Combination Therapy Average Cost Analysis (US$), 2017

Figure 10-19: US - Brentuximab Vedotin Price Analysis, (US$), 2017

Figure 10-20: US - Brentuximab Vedotin Treatment Expenditure (US$), 2014

Figure 10-21: US - Brentuximab Vedotin Treatment Cost (US$), 2017

Figure 10-22: Global - Gemtuzumab Ozogamicin Treatment Cycle Price Analysis (US$), 2010 and 2017

Figure 10-23: US - Ibritumomab Tiuxetan Product and Dose Price Analysis (US$), 2017

Figure 10-24: US - Blinatumomab Dosage Average Price Analysis (US$), 2017

Figure 10-25: US - Blinatumomab Treatment First Cycle Average Cost (US$), 2017

Figure 10-26: US - Blinatumomab Treatment Subsequent Cycle Average Cost (US$), 2017

Figure 12-1: Global CD Antigen Based Cancer Therapy Market Driving Factors

Figure 12-2: Gemtuzumab vs Best Available Therapy Survival Rate

Figure 12-3: Global CD Antigen Based Cancer Therapeutic Market Challenges

Table 10-1: Rituximab Dosage Indications for Treatment of Different Cancer Conditions

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

“CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023” report highlights:

Market Opportunity Assessment: More than US$ 60 Billion by 2023

Clinical and Patent Insight on 17 Commercialize CD Antigen Drugs

Clinical and Licensing Insight on 184 CD Antigens in Clinical Pipeline

Dosage and Price Analysis on Key Drugs

Mechanism of CD Antigen Cancer Therapeutics

Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs

Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

1. Introduction to CD Antigen Based Cancer Therapeutics

1.1 Prologue to CD Antigens

1.2 Background: Discovering CD Antigens in Cancer Therapy

1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics

2. Significance of CD Antigens: Normal Cells versus Cancer Cells

2.1 CD Antigens in Normal Cells

2.2 CD Antigens in Cancer

3. Working Mechanism of CD Antigen Based Cancer Therapeutics

4. Commercial Cancer Therapeutics Based on CD Antigens

4.1 Monoclonal Antibodies

4.2 Antibody Drug Conjugates

4.3 Bispecific Antibodies

5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics

5.1 CAR-T Cell Therapy

5.2 Aptamers

5.3 Immunoconjugates

5.3.1 Radio Immunoconjugate

5.3.2 Toxin Immunoconjugate

5.4 Novel CD Antigen Based Antibodies

5.4.1 Bispecific T-Cell Engager Antibody (BiTEs)

5.4.2 DART and TandAb

6. Major CD Antigens as Targets for Cancer Therapy

6.1 CD20

6.2 CD19

6.3 CD137

6.4 CD38

6.5 CD70

6.6 CD22

6.7 CD30

6.8 CD33

6.9 CD37

7. Major CD Antigens as Cancer Diagnostic Agents

7.1 CD20

7.2 CD5

7.3 CD56

7.4 CD66e

7.5 CD15

7.6 CD30

7.7 CD3

8. Major CD Antigens in Cancer Research

8.1 CD34

8.2 CD10

8.3 CD26

8.4 CD117

8.5 CD44

8.6 CD57

9. Global CD Antigen Based Therapeutics Market Overview

9.1 Market Progression

9.2 Current Market Scenario

9.3 Global CD Antigen Based Cancer Therapeutics Market Trends

9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview

10. Price and Dosage Analysis of Major CD Antigen Based Cancer Therapies

10.1 Rituximab (CD20)

10.2 Ofatumumab (CD20)

10.3 Obinutuzumab (CD20)

10.4 Daratumumab (CD38)

10.5 Brentuximab Vedotin (CD30)

10.6 Gemtuzumab Ozogamicin (CD33)

10.7 Inotuzumab Ozogamicin (CD22)

10.8 Ibritumomab Tiuxetan (CD20)

10.9 Blinatumomab (CD19, CD3)

10.10 Tisagenlecleucel (CD19)

11. Marketed Cancer CD Antigen Inhibitors Clinical and Patent Insight

11.1 Rituximab (MabThera and Rituxan)

11.2 Obinutuzumab (Gazyva and Gazyvaro)

11.3 Ibritumomab Tiuxetan (Zevalin and Zevamab)

11.4 Rituximab Biosimilar (AcellBia and USMAL)

11.5 Rituximab Biosimilar (Reditux and Tidecron)

11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima and Tuxella)

11.7 Rituximab Biosimilar (Novex)